Haemonetics以1亿欧元收购Vivasure Medical，以扩展无缝血管闭合技术。 Haemonetics buys Vivasure Medical for €100M to expand sutureless vascular closure tech.

Haemonetics公司以1亿欧元的预付款收购了爱尔兰的Vivasure Medical，潜在里程碑付款最高可达8500万欧元，以扩展其血管闭合服务。 Haemonetics Corp. has acquired Ireland’s Vivasure Medical for €100 million upfront, with up to €85 million in potential milestone payments, to expand its vascular closure offerings. 这笔交易以Vivasure的PerQseal Elite系统为中心,这是一个无缝、可生物吸收的装置,用于关闭大波动脉和静脉出入点,在欧洲和美国林业发展局的审查下获得批准。 The deal centers on Vivasure’s PerQseal Elite system, a sutureless, bioabsorbable device for closing large-bore arterial and venous access sites, approved in Europe and under U.S. FDA review. 由Haemonetics现金资助的购置项目旨在加强其在结构心脏和内心手术程序中的地位,该公司预计将在2月提供进一步的整合最新情况。 The acquisition, funded with Haemonetics’ cash, aims to strengthen its position in structural heart and endovascular procedures, with the company expecting to provide further integration updates in February.